Nitric oxide in tumour biology and cancer therapy. Part 1: Physiological aspects

Clinical Oncology

Volumn 9, Issue 5, 1997, Pages 282-293

  Tozer, G M ^a   Everett, S A ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ARGININE DERIVATIVE; CYTOTOXIC AGENT; HEMOGLOBIN; IMIDAZOLINE DERIVATIVE; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SCAVENGER; TUMOR PROTEIN; VASCULOTROPIN; VASODILATOR AGENT;

ANGIOGENESIS; ANIMAL TISSUE; BIOCHEMISTRY; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; CANCER THERAPY; CELL ACTIVITY; CELL PROTECTION; CYTOCHEMISTRY; CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; HYPOXIA; LEUKOCYTE ADHERENCE; METABOLIC ACTIVATION; METABOLIC REGULATION; NONHUMAN; OXYGEN SUPPLY; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; SMOOTH MUSCLE RELAXATION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; SYNTHESIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR GROWTH; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0030665017     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(05)80061-5     Document Type: Review

References (136)

1. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994;343:1199-205.
2. Kerwin JF, Heller M. The arginine-nitric oxide pathway: a target for new drugs. Med Res Rev 1994;14:23-74.
3. Kerwin JF, Lancaster JR, Feldman PL. Nitric oxide: a new paradigm for second messengers. J Med Chem 1995;38:4343-62.
4. Butler AR, Williams DLH. The physiological role of nitric oxide. Chem Soc Rev 1993;23:233-41
5. Feldman PL, Griffith OW, Stuehr DJ. The suprising life of nitric oxide. Chem Eng News 1993;71(51):26-38.
6. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-42.
7. Pörsti I, Paakkari I. Nitric oxide-based possibilities for pharmacotherapy. Ann Med 1995;27:407-20.
8. Kelly R, Balligand J-L, Smith T. Nitric oxide and cardiac function. Circ Res 1996;79:363-80.
9. Moncada S, Higgs E. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995;9:1319-30.
10. Szabó C. Alterations in nitric oxide production in various forms of circulatory shock. New Horizons 1995;3:2-32.
11. Snyder S, Bredt DS. Biological roles of nitric oxide. Sci Am 1992;(May):28-35.
12. Sagar S, Singh G, Hodson DI, et al. Nitric oxide and anticancer therapy. Cancer Treat Rev 1995;21:159-81.
13. Tozer GM, Everett SA. Nitric oxide in tumour biology and cancer therapy. Part 2: Therapeutic implications. Clin Oncol 1997;0:000-000.
14. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268:12231-4.
15. Stuehr DJ, Griffith OW. Mammalian nitric oxide synthases. Adv Enzymol 1992;65:287-346.
16. ω-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. J Biol Chem 1991;266:6259-63.
17. Nathan C, Xie Q-W. Nitric oxide syntheses: roles, tolls, and controls. Cell 1994;78:915-8.
18. Korth H-G, Sustmann R, Thater C, et al. On the mechanism of nitric oxide synthase catalysed conversion of Nω-hydroxy-L-arginine to citrulline and nitric oxide. J Biol Chem 1994;269:17776-9.
19. Abu-Soud H, Rousseau DL, Stuehr DJ. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. J Biol Chem 1993;90:10769-72.
20. Presta A, Liu J, Sessa WC, et al. Substrate binding and calmodulin binding to endothelial nitric oxide synthase coregulate its enzymatic activity. Nitric Oxide 1997;1:74-87.
21. Lancaster JR. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide 1997;1:18-30.
22. Lipton SA, Choi Y-B, Pan Z-H, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993;364:626-31.
23. Butler AR, Flitney FW, Williams DLH. NO, nitrosonium ions, nitrosothiols and iron-nitrosyls in biology, a chemist's perspective. Trends Pharmacol Sci 1995;16:18-22.
24. Stamler JS, Simon DI, Osborne JA, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 1992;89:444-8.
25. Stamler JS. Redox signalling: nitrosylation and related target interactions of nitric oxide. Cell 1994;78:931-6.
26. Marletta MA. Approaches toward selective inhibition of nitric oxide synthase. J Med Chem 1994;37:1899-907.
27. Southan GJ, Szabó C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996;51:383-94.
28. Buttery LDK, Springall DR, Andrade SP, et al. Induction of nitric oxide synthase in neo-vasculature of experimental tumours in mice. J Pathol 1993;171:311-9.
29. Thomsen LL, Miles DW, Happerfield L, et al. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995;72:41-44.
30. Thomsen LL, Laston FG, Knowles RG. et al. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994;54:1352-4.
31. Moochhala S, Chhatwal V, Chan S, et al. nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis 1996;17:1171-4.
32. Cobbs CS, Brenman JE, Aldape KD, et al. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995;55:727-30.
33. Rosbe KW, Prazma J, Petrusz P, et al. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 1995;113:541-9.
34. Doi K, Akaike T, Horie H, etal. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 1996;77:1598-604.
35. Bastian NR, Yim C-Y, Hibbs JBJ, et al. Induction of iron-derived EPR signals in murine cancers by nitric oxide. Evidence for multiple intracellular targets. J Biol Chem 1994;269:5127-31.
36. Akaike T, Maeda H. Direct quantitation of nitric oxide released from cells using liposome-encapsulated PTIO. In: Moncada S, Stamler J, Gross S, et al., editors. The biology of nitric oxide Part 5. London: Portland Press, 1996;171.
37. Vaupel PW. Blood flow, oxygenation, tissue pH distribution and bioenergetic status of tumors. Berlin: Ernest Schering Research Foundation, 1994.
38. Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 1987;47:597-601.
39. Chaplin DJ, Hill SA. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer 1995;71:1210-3.
40. Vaupel P. Oxygenation of human tumors. Strahlenther Oncol 1990;166:377-86.
41. Mueller-Klieser W, Vaupel P, Manz R. Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int J Radiat Oncol Biol Phys 1981;7:1397-404.
42. Dachs GU, Stratford IJ. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Br J Cancer 1996;74(Suppl XXVII):S126-32.
43. Hampl V, Cornfield DN, Cowan NJ, et al. Hypoxia potentiates nitric oxide synthesis and transiently increases cystosolic calcium levels in pulmonary artery endothelial cells. Eur Resp J 1995;8:515-22.
44. Park KH, Rubin LE, Gross SS, et al. Nitric oxide is a mediator of hypoxic coronary vasodilatation: relation to adenosine and cyclooxygenase-derived products. Circ Res 1992;71:992-1001.
45. Brown IP, Thompson CI, Belloni FL. Role of nitric oxide in hypoxic coronary vasodilatation in isolated perfused guinea pig heart. Am J Physiol 1993;264:H821-9.
46. Blitzer ML, Loh E, Roddy M-A, et al. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol 1996;28:591-6.
47. Sun M-K, Reis DJ. Evidence nitric oxide mediates the vasodepressor response to hypoxia in sino-denervated rats. Life Sci 1992;50:555-65.
48. Fohl U, Busse R. Hypoxia stimulates release of endothelium-derived relaxant factor. Am J Physiol 1989;256:H1595-600.
49. Ohigashi T, Brookins J, Fisher JW. Interaction of nitric oxide and cyclic guanosine 3′,5′-monophosphate in erythropoietin production. J Clin Invest 1993;92:1587-91.
50. Yoshioka K, Fisher JW. Nitric oxide enhancement of erythropoietin production in the isolated perfused rat kidney. Am J Physiol 1995;269:C917-22.
51. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994;269:4355-9.
52. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. J Clin Invest 1995;95:1798-807.
53. Adams GE, Stratford IJ. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Phys 1994;29:231-8.
54. Melillo G, Musso T, Sica A, et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995;182:1683-93.
55. Stark WW, Wasserloos K, Modzelewski R, et al. Hypoxia stimulates NF-κB mediated iNOS expression in tumor endothelial cells. Mol Biol Cell 1995;6:438a.
56. Verovski B, Bols B, Van den Berg D, et al. Mechanism of production and radiosensitizing effect of nitric oxide generated by chemical donors and nitric oxide synthase. In: Proceedings of 88th Annual Meeting of the American Association for Cancer Reseach; San Diego, CA. 1997:43.
57. Arnet U, McMillan A, Dinerman J, et al. Regulation of endothelial nitric-oxide synthase during hypoxia. J Biol Chem 1996;271:15069-73.
58. Liao JK, Zulueta JJ, Yu F-S, et al. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J Clin Invest 1995;96:2661-6.
59. McQuillan LP, Leung GK, Marsden PA, et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranslational mechanisms. Am J Physiol 1994;267: H1921-7.
60. Phelan M, Faller D. Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J Cell Physiol 1996;167:469-76.
61. Shaul PW, North AJ, Brannon TS, et al. Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung. Am J Respir Cell Mol Biol 1995;13:167-74.
62. Kim N, Vardi Y, Padma-Nathan H, et al. Oxygen tension regulates the nitric oxide pathway: physiological role in penile erection. J Clin Invest 1993;91:437-42.
63. Abu-Soud H, Rousseau DL, Stuehr DJ. Nitric oxide binding to the heme of neuronal nitric-oxide synthase links its activity to changes in oxygen tension. J Biol Chem 1996;271:32515-8.
64. Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987;39:163-96.
65. Vaandrager A, de Jonge H. Signalling by cGMP-dependent protein kinases. Mol Cell Biochem 1996;157:23-30.
66. Wolin MS, Wood KS, Ignarro GJ. Guanylate cyclase from bovine lung. A kinetic analysis of the regulation of the unpurified soluble enzyme by protoporphyrin IX, heme and nitrosyl-heme. J Biol Chem 1982;257:13312-20.
67. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
68. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from retractor penis in inorganic nitrate and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM, editor. Vasodilatation: vascular smooth muscle, peptides, autonomic nerves and endothelium. New York: Raven Press, 1988:401-14.
69. Ignarro LJ, Byrns RE, Wood KS. Biochemical and pharmacological properties of endothelium-derived relaxing factor and its similarity to nitric oxide radical. In: Vanhoutte PM, editor. Vasodilatation: vascular smooth muscle, peptides, autonomic nerves and endothelium. New York: Raven Press, 1988:427-36.
70. Ignarro LJ, Byrns RE, Buga GM, et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987;61:866-79.
71. Ignarro LJ, Buga GM, Wood KS, et la. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9.
72. Palmer RMJ, Ferrige AG, Moncada S. The release of nitric oxide by vascular endothelial cells accounts for the activity of EDRF. Nature 1987;327:524-6.
73. Luscher TF, Yang Z, Tschudi M, et al. Interaction between endothelin-1 and endothelium derived relaxing factor in human arteries and veins. Circ Res 1990;66:1088-94.
74. Rees DD, Palmer RMJ, Schulz R, et al. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990;101:746-52.
75. Gardiner SM, Kemp PA, March JE, et al. Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats. Br J Pharmacol 1995;116:2005-16.
76. Tozer GM, Prise VE, Chaplin DJ. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 1997;57:948-55.
77. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239-42.
78. Vanhoutte PM, Mombouli J-V. Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis 1996;39:229-38.
79. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250:H1145-1149.
80. Koller A, Kaley G. Shear stress dependent regulation of vascular resistance in health and disease: role of endothelium. Endothelium 1996;4:247-72.
81. Jia L, Bonaventura C, Bonaventura J, et al. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996;380:221-6.
82. Mellion BT, Ignarro LJ, Ohlstein EH, et al. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981;57:946-55.
83. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986;88:411-5.
84. Busse R, Lückhoff A, Bassenge E. Endothelium-derived relaxant factor inhibits platelet activation. Naunyn-Schmiedebergs Arch Pharmacol 1987;336:566-71.
85. Furlong B, Henderson AH, Lewis MJ, et al. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol 1987;90:687-92.
86. Radomski MW, Palmer RMJ, Moncada S. The antiaggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639-46.
87. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987;92:181-7.
88. 2+ and an aggregation of human platelets. Eur J Pharmacol 1993;244:37-47.
89. Golino P, Cappelli-Bigazzi M, Ambrosio G, et al. Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circ Res 1992;71:1447-56.
90. Yao S-K, Ober JC, Krishnaswami A, et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 1992;86:1302-9.
91. Calver A, Collier J, Vallance P. Nitric oxide and cardiovascular control. Exp Physiol 1993;78:303-26.
92. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/ nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-7.
93. Ware JA, Johnson PC, Smith M, et al. Effect of common agonists on cytoplasmic ionized calcium concentration in platelets. Measurement with 2-methyl-6-methoxy-8-nitroquinoline (Quin2) and aequorin. J Clin Invest 1986;77:878-86.
94. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1057-8.
95. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987;148:1482-9.
96. Sneddon JM, Vane JR. endothelium-derived relaxing factors reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci USA 1988;85:2800-804.
97. Siney L, Lewis MJ. Endothelium-derived relaxing factor inhibits platelet adhesion to cultured porcine endocardial endothelium. Eur J Pharmacol 1992;229:223-6.
98. de Graaf JC, Banga JD, Moncada S, et al. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992;85:2284-90.
99. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.
100. Biffl W, Moore E, Moore F, et al. Nitric oxide reduces endothelial expression of intercellular adhesion molecule (ICAM)-1. J Surg Res 1996;63:328-32.
101. Khan B, Harrison D, Olbrych M, et al. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996;93:9114-9.
102. Nolte C, Eigenthalter M, Schanzenbächer P, et al. Endothelial cell-dependent phosphorylation of a platelet protein mediated by cAMP- and cGMP-elevating factors. J Biol Chem 1991;266:14808-12.
103. Durante W, Kroll MH, Vanhoutte PM, et al. Endothelium-derived relaxing factor inhibits thrombin-induced platelet aggregation by inhibiting platelet phospholipase C. Blood 1992;79:110-6.
104. Peterson H-I. Modification of tumour blood flow - a review. Int J Radiat Biol 1991;60:201-10.
105. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature. Br J Pharmacol 1992;107:1092-5.
106. Wood P, Stratford IJ, Adams GE, et al. Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem Biophys Res Commun 1993;192:505-10.
107. G-nitro-L-arginine. Cancer Res 1994;54:6458-63.
108. Wood PJ, Sansom JM, Stratford IJ, et al. Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine. Int J Radiat Oncol Biol Phys 1994;29:443-7.
109. Meyer RE, Shan S, DeAngelo J, et al. Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br J Cancer 1995;71:1169-74.
110. Fukumura D, Yuan F, Endo M, et al. Role of nitric oxide in tumour microcirculation. Am J Pathol 1997;150:713-25.
111. Horsman MR, Chaplin DJ, Hill SA, et al. Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Br J Cancer 1996;74(Suppl XXVII):S168-71.
112. Hahn JS, Braun RD, Dewhirst MW, et al. Storma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressure. Radiat Res 1997;147:185-94.
113. Maeda H, Akaike T, Yoshida M, et al. Multiple functions of nitric oxide in pathophysiology and microbiology: analysis by a new nitric oxide scavenger. J Leukoc Biol 1994;56:588-92.
114. Maeda H, Noguchi Y, Sato K, et al. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994;85:331-4.
115. Yoshida M, Akaike T, Wada Y, et al. Therapeutic effects of imidazolineoxyl N-oxide against endotoxin shock through its direct nitric oxide-scavenging activity. Biochem Biophys Res Commun 1994;202:923-30.
116. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol 1992;262:H611-5.
117. Dvorak HF, Nagy JA, Dvorak JT, et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133:95-109.
118. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1995;1:27-31.
119. Folkman J. Tumour angiogenesis. Adv Cancer Res 1985;43:175-203.
120. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994;94:2036-44.
121. Leibovich SJ, Polverini PJ, Fong TW, et al. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci USA 1994;91:4190-4.
122. Konturek SJ, Brzozowski T, Majka J, et al. Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol 1993;239:215-7.
123. Brzozowski T, Konturek SJ, Drozdowicz D, et al. Healing of chronic gastric ulcerations by L-arginine. Digestion 1995; 56:463-71.
124. Benrath J, Zimmermann M, Gillardon F. Substance P and nitric oxide mediate wound healing of ultraviolet photo-damaged rat skin: evidence for an effect of nitric oxide on keratinocyte proliferation. Neurosci Lett 1995;200:17-20.
125. Yang W, Ando J, Korenga R, et al. Exogenous nitric oxide inhibits proliferation of cultured vascular endothelial cells. Biochem Biophys Res Commun 1994;203:1160-67
126. Lau Y-T, Ma W-C. Nitric oxide inhibits migration of cultured endothelial cells. Biochem Biophys Res Commun 1996;221:670-4.
127. Pipili-Synetos E, Sakkoula E, Haralabopoulos G, et al. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 1994;111:894-902.
128. Hatjikondi O, Ravazoula P, Kardamakis D, et al. In vivo experimental evidence that the nitric oxide pathway is involved in the X-ray-induced antiangiogenicity. Br J Cancer 1996;74:1916-23.
129. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
130. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
131. Kondo S, Asano M, Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993;194:1234-41.
132. Mazure NM, Chen EY, Yeh P, et al. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996;56:3436-40.
133. Bolotina VM, Najibi S, Palacino JJ, et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994;368:850-3.
134. Loesch A, Turmaine M, Loizidou M, et al. Electron-immunocytochemistry of blood vessels in rat liver metastates: experimental sarcoma and carcinoma. J Anat, in press.
135. Nakano S, Matsukado K, Black KL. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res 1996;56:4027-31.
136. Thomsen LL, Miles DW, Happerfield L, et al. Nitric oxide synthase in human breast cancer tissue is localized within macrophages. In: Moncada S, Feelisch M, Busse R, et al, editors. The biology of nitric oxide 4: Enzymology, biochemistry and immunology. London: Portland Press, 1994:463-6.